- find opportunities in the treatment of those disorders
What are the commercial prospects for the treatment of macular degeneration (AMD) and diabetic retinopathy (DR)? Our new report shows you potential revenues to 2021, discussing commercial opportunities and prospects.
Our report gives you market forecasts to 2021 for those retinal drugs. Discover potential revenues at total world, submarket, product and national levels. Through our research and analysis we aim to save you time and help in your decisions. Find data you need.
See how the drugs Lucentis, Visudyne, Avastin and Macugen can perform to 2021, finding potential revenues. For your needs, we discuss competition in this expanding market.
Our study discusses Roche, Novartis, Pfizer, Sanofi and other companies. There are many opportunities in AMD and DR for large and niche players. Discover prospects for existing competitors and potential market entrants from 2011 to 2021.
There is a strong R&D pipeline for treating retinal disorders. We cover products in development by Regeneron, Bayer, Allergan, OPKO, GSK, Merck, Eli Lilly, Takeda and others. Find R&D trends there.
Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Original analysis with revenues, growth rates, market shares, opinion and discussions
In our report you find revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinions from our survey. We provide 153 tables and charts and three research interviews (shown in the accompanying lists).
Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021 shows you opportunities, challenges and revenue forecasts
Our report gives you the following advantages
• Find revenue predictions to 2021 for the world AMD and DR market and its components, seeing revenue growth
• See revenue forecasts to 2021 for leading products, assessing market potentials and competition
• Discover revenue forecasts to 2021 for leading national markets - US, Japan, UK, Germany, France, Spain, Italy, China and India
• Receive supporting data, including epidemiological trends and projections
• Assess leading companies providing retinal treatments, discovering their activities and outlooks
• Find out how the retinal drug industry can change and adapt from 2011 to 2021
• Investigate competition and opportunities influencing the industry and market
• See what will stimulate and restrain the industry and market from 2011
• Review R&D for AMD and DR, seeing potential for new products and drug types
• Investigate commercial requirements, identifying therapeutic needs and opportunities
• Analyse opportunities and challenges for established and emerging companies
• View opinions from three interviews with authorities on retinal treatments.
There, you find a distinctive mix of quantitative and qualitative analysis with original predictions. We tackle crucial questions for AMD and DR, helping you to stay ahead.
Order our report now to gain industry and market analysis for AMD and DR
Our report is for everybody interested in industry and market analysis for the treatment of retinal disorders. Find trends and answers. Don’t miss out - please order our report now.
1. Executive Summary
1.1 Macular Degeneration (AMD) and Diabetic Retinopathy (DR): Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods
2. AMD and DR: An Introduction
2.1 The Biology of Vision
2.1.1 The Human Eye
2.1.2 The Retina and the Vision Process
2.2 Age-Related Macular Degeneration (AMD)
2.2.1 Early Stages of AMD
2.2.2 Advanced Dry AMD (Geographic Atrophy)
2.2.3 Wet AMD
2.2.4 Causes and Risk Factors for AMD
2.3 Diabetic Retinopathy (DR)
2.3.1 Causes and Types of Diabetic Retinopathy
2.3.2 Non-Proliferative Diabetic Retinopathy
2.3.3 Diabetic Macular Oedema
2.3.4 Proliferative Diabetic Retinopathy
2.3.5 Risk Factors for Diabetic Retinopathy
2.4 Diagnosis
2.5 Epidemiology
3. The Global AMD and DR Market 2011-2021
3.1 Global AMD and DR Market, 2011-2021
3.2 Market Breakdown, 2011-2021
3.3 The Ophthalmic Market, 2011-2021
3.3.1 Other Retinal Disorders
4. Regional AMD and DR Markets 2011-2021
4.1 The US Dominated the AMD and DR Drug Market in 2010
4.2 The US: Leading the AMD and DR Market, 2011-2021
4.2.1 Forecast for the US Market, 2011-2021
4.3 Japan: Second-Largest Market, 2011-2021
4.3.1 Forecast for the Japanese Market, 2011-2021
4.4 The EU Top Five: Rising Healthcare Costs, 2011-2021
4.4.1 Forecast for the French Market, 2011-2021
4.4.2 Forecast for the German Market, 2011-2021
4.4.3 Forecast for the UK Market, 2011-2021
4.4.4 Forecast for the Spanish Market, 2011-2021
4.4.5 Forecast for the Italian Market, 2011-2021
4.5 India: Diabetes Epidemic Drives the Market, 2011-2021
4.5.1 Forecast for the Indian Market, 2011-2021
4.6 China: The Fastest-Growing Market, 2011-2021
4.6.1 Forecast for the Chinese Market, 2011-2021
5. Leading Products in the AMD and DR Market 2011-2021
5.1 Lucentis Dominates the Market in 2011
5.2 Lucentis (Roche/Novartis): Most Successful Ophthalmic Drug
5.2.1 Forecast for Lucentis, 2011-2021
5.3 Visudyne (QLT / Novartis): Treatment for Classic AMD
5.3.1 Forecast for Visudyne, 2011-2021
5.4 Avastin (Roche): Off-Label Competitor to Lucentis
5.4.1 The CATT Study: The Verdict on Avastin versus Lucentis
5.4.2 Forecast for Avastin, 2011-2021
5.5 Macugen (Pfizer): Alternative VEGF Antagonist
5.5.1 Forecast for Macugen, 2011-2021
5.6 Eylea (Regeneron/Bayer): The Next Blockbuster
5.6.1 Forecast for Eylea, 2011-2021
5.7 Other Products in the Market
5.7.1 Treatments for Dry AMD
5.7.2 Treatments for DR
5.7.2.1 Triamcinolone Acetonide (Various Companies)
5.7.2.2 Lisinopril (Various Companies)
5.7.2.3 Avastin (Roche)
5.7.2.4 Dobesilate (Various Companies)
5.7.3 Forecast for Other Products in the Market, 2011-2021
6. The AMD and DR Product Pipeline, 2011
6.1 AMD Products
6.1.1 Eylea (Regeneron/Bayer)
6.1.2 Posurdex/SK-503 (Allergan)
6.1.3 Bevasiranib/Cand5 (OPKO)
6.1.4 Pazopanib (GlaxoSmithKline)
6.1.5 NT501 (Neurotech)
6.1.6 Zybrestat (Oxigene/Symphony ViDA)
6.1.7 Brimonidine (Allergan)
6.1.8 Sirolimus (MacuSight/Santen)
6.1.9 Iluvien (Alimera/pSivida)
6.1.10 RTP801i-14/PF-4523655/PF-655 (Quark/Silence/Pfizer)
6.1.11 AGN-745/SIRNA-027 (Merck & Co./Allergan)
6.1.12 ATG-3 (CoMentis)
6.1.13 OT-551 (Othera)
6.1.14 Fenretinide (Sirion Therapeutics)
6.1.15 Early-Stage Products
6.2 DR Products
6.2.1 Arxxant (Eli Lilly/Alcon/Takeda)
6.2.2 Vitreosolve (Vitreoretinal Technologies)
6.2.3 Atacand/TCV-116 (AstraZeneca/Takeda)
6.2.4 Microplasmin (Thrombogenics)
6.2.5 Products Also Indicated for AMD
6.2.6 Early-Stage DR Products
7. Leading Companies in the AMD and DR Market, 2011
7.1 Pharmaceutical Industry Leaders
7.1.1 Novartis
7.1.2 Roche
7.1.3 Pfizer
7.1.4 Sanofi
7.1.5 Other Big Pharma Players
7.2 Smaller Companies
7.2.1 Allergan
7.2.2 BioDiem
7.2.3 CoMentis
7.2.4 Alimera Sciences
7.2.5 Gene Signal
7.2.6 GenVec
7.2.7 ISTA Pharmaceuticals
7.2.8 Shire
7.2.9 KAI Pharmaceuticals
7.2.10 Lpath
7.2.11 Santen
7.2.12 Neurotech
7.2.13 Ophthotech Corporation
7.2.14 OPKO Health
7.2.15 Othera Pharmaceuticals
7.2.16 Oxford BioMedica
7.2.17 Oxigene
7.2.18 Potentia
7.2.19 Regeneron
7.2.20 Sirion Therapeutics
7.2.21 Sirnaomics
7.2.22 AmpliPhi Biosciences Corporation
7.2.23 ThromboGenics
8. The AMD and DR Market: Qualitative Analysis
8.1 The AMD and DR Market is Well Established and Growing
8.2 Products are Few, Inconvenient and Expensive, Some People Believe
8.3 Global Demography and the Diabetes Epidemic Mean Governments Will Keep Paying
8.4 Is Pharmaceutical Treatment the Future for Ophthalmics Disorders?
9. Research Interviews
9.1 Interview with Professor David T. Shima, University College London
9.1.1 On the Role of VEGF in Retinal Disorders
9.1.2 On Candidate Molecule E10030
9.1.3 On Candidate Molecule JSM 6427
9.1.4 On New Sustained Release Formulations
9.1.5 On Delta-Notch Signalling
9.1.6 On Potential Clinical Crossovers Between Ophthalmology and Oncology
9.1.7 On the Commercial and Clinical Possibilities in the Ophthalmology Market
9.1.8 On the Possibilities of Research into the Endothelial Fenestra
9.2 Interview with Dr Edward Feener, Joslin Diabetes Center
9.2.1 On the Kallikrein Pathway in Disease Etiology
9.2.2 On the Use of Proteomics in Research
9.2.3 On Challenges in Diabetic Retinopathy
9.2.4 On Plasma Kallikrein Inhibitors, Prevention, and Other Future Prospects in the Sector
9.3 Interview with Dr Paul Ashton, pSivida
9.3.1 On the Challenge of Getting Drugs to the Retina
9.3.2 On pSivida’s Drug Delivery Platforms
9.3.3 On Lucentis, Avastin and VEGF-Trap
10. Conclusions
10.1 The AMD and DR Market is Likely to Expand
10.2 The Issue of Avastin versus Lucentis Has Dominated the Sector
10.3 Regeneron’s Eylea as the Next New Product on the Market
10.4 The Pipeline for AMD and DR is Rich and Diverse
10.5 Concluding Remarks
List of Tables
Table 2.1 Leading Causes of Blindness, Number of Cases (m), Proportion of Total (%), 2007
Table 2.2 Types of CNV in Wet AMD
Table 2.3 AMD and DR Diagnosis Methods, 2011
Table 2.4 Incidence (m) and Prevalence (m) of Advanced AMD and DR, 2010
Table 3.1 Global AMD/DR Market Forecast: Sales ($m), AGR (%), CAGR (%), 2010-2015
Table 3.2 Global AMD/DR Market Forecast: Sales ($m), AGR (%), CAGR (%), 2016-2021
Table 3.3 AMD Market Segment and DR Market Segment: Sales ($m), Market Shares (%), 2010, 2015, 2021
Table 3.4 Global AMD and DR Markets Forecast: Sales ($m), AGR (%), CAGR (%), 2010-2015
Table 3.5 Global AMD and DR Markets Forecast: Sales ($m), AGR (%), CAGR (%), 2016-2021
Table 3.6 The Ophthalmic Pharmaceuticals Market: Submarkets, Sales ($m), Market Shares (%), 2010
Table 3.7 Other Retinal Disorders Market Forecast: Sales ($m), AGR (%), CAGR (%), 2010-2015
Table 3.8 Other Retinal Disorders Market Forecast: Sales ($m), AGR (%), CAGR (%), 2016-2021
Table 3.9 Some Other Retinal Disorders
Table 4.1 Leading National Markets, AMD and DR Drugs: Sales ($m), Market Shares (%), 2010
Table 4.2 Leading National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.3 Leading National Markets, AMD and DR Drugs: Sales ($m), Market Shares (%), 2015
Table 4.4 Leading National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.5 Leading National Markets, AMD and DR Drugs: Sales ($m), Market Shares (%), 2021
Table 4.6 US and Leading Five EU National Markets: Drug Prices Relative to the UK, 2008
Table 4.7 Healthcare Expenditure as Percentage of GDP in Leading Countries, 2010
Table 4.8 Population (m) Over 65 Years of Age in Leading Countries, at Five-Yearly Intervals, 2000-2030
Table 4.9 Population (%) Over 65 Years of Age in Leading Countries, at Five-Yearly Intervals, 2000-2030
Table 4.10 Prevalence of Diabetes in Leading Markets (m and % of Population), 2000 and 2030
Table 4.11 US: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.12 US: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.13 Japan: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.14 Japan: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.15 EU Leading Five Markets: AMD and DR Drugs, Sales ($m), EU Market Shares (%), 2010, 2015, 2021
Table 4.16 Leading Five EU Markets: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.17 Leading Five EU Markets: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.18 France: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.19 France: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.20 Germany: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.21 Germany: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.22 UK: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.23 UK: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.24 Spain: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.25 Spain: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.26 Italy: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.27 Italy: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.28 India: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.29 India: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 4.30 China: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.31 China: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 5.1 Leading Products in the AMD and DR Drugs Market: Sales ($m), Market Shares (%), 2010
Table 5.2 Leading Products in the AMD and DR Drugs Market: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 5.3 Leading Products in the AMD and DR Drugs Market: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 5.4 Lucentis Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 5.5 Lucentis Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 5.6 Visudyne Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 5.7 Visudyne Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 5.8 Avastin Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 5.9 Avastin Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 5.10 Macugen Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 5.11 Macugen Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 5.12 Eylea Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 5.13 Eylea Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 5.14 Other Products Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 5.15 Other Products Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Table 6.1 AMD Pipeline, Phase II and Later, 2011
Table 6.2 AMD Pipeline, Phase I and Preclinical, 2011
Table 6.3 DR Pipeline, Phase II and Later, 2011
Table 6.4 DR Pipeline, Phase I and Preclinical, 2011
Table 8.1 SWOT Analysis of AMD and DR Market, 2011
List of Figures
Figure 2.1 Leading Causes of Blindness, Number of Cases (m), Proportion of Total (%), 2007
Figure 2.2 Stages and Progression of AMD
Figure 2.3 Types of CNV in Wet AMD, Approximate Proportion of Cases (%), 2010
Figure 2.4 Incidence (m) and Prevalence (m) of Advanced AMD and DR, 2010
Figure 3.1 Global AMD/DR Market Forecast: Sales ($m), 2010-2015
Figure 3.2 Global AMD/DR Market Forecast: Sales ($m), 2016-2021
Figure 3.3 AMD Market Segment and DR Market Segment: Sales ($m), Market Shares (%), 2010
Figure 3.4 AMD Market Segment and DR Market Segment: Sales ($m), Market Shares (%), 2015
Figure 3.5 AMD Market Segment and DR Market Segment: Sales ($m), Market Shares (%), 2021
Figure 3.6 Global AMD and DR Markets Forecast: Sales, 2010-2015
Figure 3.7 Global AMD and DR Markets Forecast: Sales, 2016-2021
Figure 3.8 Global AMD and DR Markets Forecast: Market Shares (%), 2010-2015
Figure 3.9 Global AMD and DR Markets Forecast: Market Shares (%), 2016-2021
Figure 3.10 The Ophthalmic Pharmaceuticals Market: Sales ($m), 2010
Figure 3.11 The AMD and DR Market as a Proportion of the Ophthalmic Pharmaceuticals Market: (%), 2010-2021
Figure 3.12 Other Retinal Disorders Market Forecast: Sales ($m), 2010-2015
Figure 3.13 Other Retinal Disorders Market Forecast: Sales ($m), 2016-2021
Figure 4.1 Leading National Markets, AMD and DR drugs: Sales ($m), Market Shares (%), 2010
Figure 4.2 Leading National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Figure 4.3 Leading Five EU National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Figure 4.4 Leading National Markets, AMD and DR drugs: Sales ($m), Market Shares (%), 2015
Figure 4.5 Leading National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Figure 4.6 Leading Five EU National Markets, AMD and DR Drugs, Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Figure 4.7 Leading National Markets, AMD and DR Drugs: Sales ($m), Market Shares (%), 2021
Figure 4.8 US and Leading Five EU National Markets: Drug Prices Relative to UK, 2008
Figure 4.9 Healthcare Expenditure as Percentage of GDP, Leading Countries, 2010
Figure 4.10 Population (m) Over 65 Years of Age in Leading Countries, 2000-2030
Figure 4.11 Population (m) Over 65 Years of Age in Leading Five EU Countries, 2000-2030
Figure 4.12 Population (%) Over 65 Years of Age in Leading Countries, 2000-2030
Figure 4.13 Population (%) Over 65 Years of Age in Leading Five EU Countries, 2000-2030
Figure 4.14 Prevalence of Diabetes in Leading Markets (m), 2000 and 2030
Figure 4.15 Prevalence of Diabetes in Leading Markets (%), 2000 and 2030
Figure 4.16 US: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
Figure 4.17 US: Population Over 65 (%), Population with Diabetes (m), 2000 and 2030
Figure 4.18 US: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Figure 4.19 US: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Figure 4.20 Japan: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
Figure 4.21 Japan: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
Figure 4.22 Japan: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Figure 4.23 Japan: AMD and DR Drugs, Market Forecast: Sales ($m), AGR (%), CAGR (%), Market Shares (%), 2016-2021
Figure 4.24 EU Leading Five Markets: AMD and DR Drugs, Sales ($m), EU Market Shares (%), 2010
Figure 4.25 EU Leading Five Markets: AMD and DR Drugs, Sales ($m), EU Market Shares (%), 2015
Figure 4.26 EU Leading Five Markets: AMD and DR Drugs, Sales ($m), EU Market Shares (%), 2021
Figure 4.27 EU Leading Five Markets: Healthcare Expenditure as Fraction of GDP (%), Population Over 65 (%), 2010
Figure 4.28 Leading Five EU Markets: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
Figure 4.29 Leading Five EU Markets: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
Figure 4.30 Leading Five EU Markets: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
Figure 4.31 Leading Five EU Markets: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
Figure 4.32 France: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
Figure 4.33 France: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
Figure 4.34 France: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
Figure 4.35 France: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
Figure 4.36 Germany: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
Figure 4.37 Germany: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
Figure 4.38 Germany: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
Figure 4.39 Germany: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
Figure 4.40 UK: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
Figure 4.41 UK: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
Figure 4.42 UK: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
Figure 4.43 UK: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
Figure 4.44 Spain: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
Figure 4.45 Spain: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
Figure 4.46 Spain: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
Figure 4.47 Spain: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
Figure 4.48 Italy: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
Figure 4.49 Italy: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
Figure 4.50 Italy: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
Figure 4.51 Italy: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
Figure 4.52 India: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
Figure 4.53 India: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
Figure 4.54 India: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
Figure 4.55 India: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
Figure 4.56 China: Population Over 65 (m), Population with Diabetes (m), 2000 and 2030
Figure 4.57 China: Population Over 65 (%), Population with Diabetes (%), 2000 and 2030
Figure 4.58 China: AMD and DR Drugs, Market Forecast: Sales ($m), 2010-2015
Figure 4.59 China: AMD and DR Drugs, Market Forecast: Sales ($m), 2016-2021
Figure 5.1 Leading Products in the AMD and DR Drugs Market: Sales ($m), Market Shares (%), 2010
Figure 5.2 Lucentis Market Forecast: Sales ($m), 2010-2015
Figure 5.3 Lucentis Market Forecast: Sales ($m), 2016-2021
Figure 5.4 Visudyne Market Forecast: Sales ($m), 2010-2015
Figure 5.5 Visudyne Market Forecast: Sales ($m), 2016-2021
Figure 5.6 Avastin Market Forecast: Sales ($m), 2010-2015
Figure 5.7 Avastin Market Forecast: Sales ($m), 2016-2021
Figure 5.8 Macugen Market Forecast: Sales ($m), 2010-2015
Figure 5.9 Macugen Market Forecast: Sales ($m), 2016-2021
Figure 5.10 Eylea Market Forecast: Sales ($m), 2010-2015
Figure 5.11 Eylea Market Forecast: Sales ($m), 2016-2021
Figure 5.12 Other Products Market Forecast: Sales ($m), 2010-2015
Figure 5.13 Other Products Market Forecast: Sales ($m), 2016-2021
Abbott Laboratories
Advanced Vision Science
Agency for Nutrition and Food Safety (Spain)
Alcon Laboratories
Alimera Sciences
Allergan
American Academy of Ophthalmology (AAO)
American Society of Retina Specialists (ASRS)
AmpliPhi Biosciences Corporation
Assogenerici (Italian Association of Generic Medicines Industry)
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Bausch & Lomb
Bayer Healthcare
Biocon
BioDiem
BioInvent International
Bristol-Myers Squibb
Cambridge University
Centre for Molecular and Vascular Biology, KU Leuven
CIBA Vision
Cipla
Claris Lifesciences
CoMentis
Control Delivery Systems
Daiichi Sankyo
Delenex Therapeutics
Diabetic Retinopathy Clinical Research Network (DRCR)
Dr. Reddy’s Laboratories
Eli Lilly
Emory University
ESBATech
Esteve
European Medicines Agency (EMA)
Eyetech Pharmaceuticals
Food and Drug Administration (US FDA)
Fovea Pharmaceuticals
Gene Signal
Genentech
GenVec
GlaxoSmithKline
Harvard Medical School
iCo Therapeutics
Institute of Experimental Medicine (St. Petersburg, Russia)
Intas Biopharmaceuticals
International Diabetes Foundation
Isis Pharmaceuticals
ISTA Pharmaceuticals
Jerini
Joslin Diabetes Center
KAI Pharmaceuticals
Lpath
Ludwig-Maximilians-Universität
Lupin Pharma
MacuSight
MedImmune
Merck & Co.
Merial
National Eye Institute (NEI)
National Health Service (NHS)
National Institute for Clinical Excellence (NICE)
Neurotech
New England Journal of Medicine (NEJM)
Nobilon International
Novartis
Novo Nordisk
Oklahoma Medical Research Foundation
OM Pharmaceuticals
Onco Therapies
Ophthotech
Opko Health
Othera Pharmaceuticals
Oxford BioMedica
Oxigene
Pfizer
Piramal Healthcare
PlaNrt Finance
Potentia Pharmaceuticals
Provincial Institute for the Control of Pharmaceutical and Biologic Products (China)
pSivida
Purdue University
QLT
Quark Pharmaceuticals
Ranbaxy Laboratories
Regeneron
Reliance Life Sciences
ReVision Therapeutics
Roche
Sanofi
Santen Pharmaceutical
Sanwa Kagaku Kenkyusho (a subsidiary of Suzuken)
Shandong University
Shanghai Institute for Biological Sciences
Shire
Silence Therapeutics
Sirion Therapeutics
Sirna Therapeutics
Sirnaomics
State Food and Drug Administration (China)
Strides Arcolab
SurModics
Symphony ViDA
Takeda Pharmaceutical Company
TargeGen
ThromboGenics
University College London
University of Florida
University of Kentucky College of Medicine
Vitreoretinal Technologies
Wockhardt
World Health Organization (WHO)
Other selected research from the 'Drugs' category:
Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021
World Anesthesia Drug Market , The
Other selected research from the 'Metabolic disorders' category:
Diabetes Care Devices Market In Brazil, Russia, India & China (BRIC) (2010 - 2014)
Osteoporosis & Bone Metabolism Disorders: World Market 2010-2025